Anupama Mohanram, MD
Nephrology · Shelbyville, INNPI 1083679724
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 39.6% of the total. Reporting peaked in 2021 at $4,532 and has fallen 70.4% since, to $1,343 in 2025. Among nephrology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $95.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- AstraZeneca$2K
- Novo Nordisk$1K
- Otsuka America Pharmaceutical, Inc.$674
- Mallinckrodt Hospital Products Inc.$494
- Bayer$402
- plus $2K from 20 others
What the payments were for
- Consulting fees$4,26938%
- Travel & lodging$2222%
- Food & beverage$6,57258%
- Education$3183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $4,505 |
| AstraZeneca | 29 | $2,162 |
| Novo Nordisk | 20 | $1,201 |
| Otsuka America Pharmaceutical, Inc. | 10 | $674 |
| Mallinckrodt Hospital Products Inc. | 7 | $494 |
| Bayer | 9 | $402 |
| Amgen(2 entities) | 3 | $313 |
| E.r. Squibb & Sons, L.L.C. | 3 | $239 |
| Madrigal Pharmaceuticals | 2 | $182 |
| Esperion Therapeutics, Inc. | 2 | $155 |
| Travere Therapeutics, Inc. | 5 | $132 |
| Lexicon Pharmaceuticals, Inc. | 1 | $126 |
| Boehringer Ingelheim | 1 | $125 |
| GSK | 1 | $122 |
| Aurinia Pharma U.S., Inc. | 1 | $116 |
| Vifor Pharma, Inc. | 5 | $100 |
| Novartis | 4 | $96 |
| Janssen Scientific Affairs, LLC | 2 | $56 |
| Boston Scientific | 1 | $44 |
| OPKO Pharmaceuticals, LLC | 3 | $29 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $21 |
| Nxstage Medical, Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,380 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $224,839 |
| FarxigaDapagliflozin Propanediol | 133 | $134,530 |
| JardianceEmpagliflozin | 67 | $61,449 |
| MounjaroTirzepatide | 39 | $53,527 |
| KerendiaFinerenone | 46 | $44,048 |
| XphozahTenapanor Hcl | 11 | $43,722 |
| RayaldeeCalcifediol | 31 | $28,582 |
| RybelsusSemaglutide | 17 | $26,565 |
| VascepaIcosapent Ethyl | 15 | $8,108 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 11 | $7,499 |
| Sevelamer Carbonate | 25 | $5,778 |
| Torsemide | 62 | $1,390 |
| Calcitriol | 144 | $1,388 |
| Spironolactone | 145 | $1,191 |
| Valsartan | 87 | $1,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,201 | $251,404187 claims |
| AstraZenecaFarxiga | $2,162 | $134,530133 claims |
| Boehringer IngelheimJardiance | $125 | $61,44967 claims |
| BayerKerendia | $402 | $44,04846 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $29 | $28,58231 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $15 | $7,49911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 nephrology providers in Indiana.
Other nephrology in Shelbyville
- Jorge DiegoShelbyville$81K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.